

X I . News Releases

Major news releases during April - September 2008 are as below.

Please refer to our web site for details (<http://www.takeda.com/>).

Date	Summary
1-Apr-08	Cell Genesys and Takeda Announce Global Alliance for the Development and Commercialization of GVAX Immunotherapy for Prostate Cancer
1-Apr-08	New Data Showed ACTOS® (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients with Type 2 Diabetes Data expands body of evidence in high risk population using IVUS, a unique marker for coronary atherosclerosis
1-Apr-08	Launch of Takeda Bio Development Center Limited
1-Apr-08	Transfer of Shares of Hitachi Inpharma, Ltd. from Takeda to Hitachi
4-Apr-08	Takeda Wins Definitive Decision in Patent Infringement Litigation on Appeal against an ANDA Filer for Generic ACTOS®
10-Apr-08	Takeda to Acquire Millennium for Us\$25.00 Per Share in an All Cash Tender Offer Valued at \$8.8 Billion -- Acquisition Accelerates Takeda's Vision of Becoming a Global Leader in Oncology --
30-Apr-08	Sucampo Pharmaceuticals Obtains FDA Approval for AMITIZA® for the Treatment of Irritable Bowel Syndrome with Constipation in Adult Women
9-May-08	Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
15-May-08	Takeda Completes Subsequent Offering Period for Shares of Millennium Pharmaceuticals, Inc.
15-May-08	Takeda Completes Acquisition of Millennium
16-May-08	Proposed Amendments of the Remuneration System For Members of Board of Directors and Corporate Auditors
26-May-08	Voglibose (BASEN®) for the prevention of type 2 diabetes mellitus: A Randomized, Double-blind Trial in Japanese Subjects with Impaired Glucose Tolerance --- Data Presented at The 51st Annual Meeting of the Japan Diabetes Society ---
27-May-08	Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics
9-Jun-08	Phase 3 Results for alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies Data from five pivotal phase 3 studies presented at the American Diabetes Association 68th Scientific Sessions
17-Jun-08	Takeda to Appeal EMEA Negative Opinion on ramelteon for the Treatment of Primary Insomnia
23-Jun-08	FDA Approves VELCADE® (BORTEZOMIB) for Injection for Patients with Previously Untreated Multiple Myeloma -- New indication offers earlier treatment options for patients --
26-Jun-08	Notice Concerning Stock Options (Stock Acquisition Rights) for Members of the Board of Directors
30-Jun-08	Takeda Submitted a New Drug Application for Anti-Cancer Agent, panitumumab (recombinant)
30-Jun-08	Launch of "ENBREL® 25mg Syringe 0.5 mL for S.C. Injection" New Formulation of ENBREL®
2-Jul-08	Takeda Pharmaceuticals and TAP Pharmaceutical Products Inc. Merge Combined Company is a Top 15 Pharmaceutical Company in the United States
8-Jul-08	Takeda Submitted a Request for Mutual Agreement Procedure Regarding a Correction Notice Based on Transfer Pricing Taxation
14-Jul-08	Notice Concerning the Determination of the Items of Stock Options (Stock Acquisition Rights) for Members of the Board of Directors
16-Jul-08	Antiosteoporotic drugs "Actonel® 17.5 mg tablets" and "Benet® 17.5 mg tablets" received approval for additional indication in patients with Paget's disease of bone: Both come in new packages.
29-Aug-08	Takeda and Affymax Provide Clinical Development Update for Hematide™ in Chemotherapy-induced Anemia -- Companies Decide to Suspend Co-Development of Hematide™ in CIA and Focuses all Efforts on Late Stage Co-Development in Chronic Renal Failure Related Anemia --
11-Sep-08	Interesting new data on the effect of candesartan on diabetic eye complications
12-Sep-08	Takeda Filed a Lawsuit Against Taiyo Pharmaceutical Industry Co., LTD. For Damages Related to Recall of Pansporin and Others
24-Sep-08	Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS® (pioglitazone HCl) for the Treatment of Type 2 Diabetes
25-Sep-08	Takeda Established a New Company for Asian Sales & Marketing
25-Sep-08	Takeda Established a New Company for Clinical Development in the Asia-Oceania Region
26-Sep-08	Takeda to Withdraw its Marketing Authorization Application for Ramelteon for the Treatment of Primary Insomnia in Europe
29-Sep-08	Takeda Submitted a New Drug Application for Alogliptin in Japan for Treatment of Type 2 Diabetes
29-Sep-08	Takeda Submitted a New Drug Application in Japan for Actos® Orally Disintegrating Tablets